Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Pertuzumab and Trastuzumab in HER2+ Breast Cancer Brain Metastases
NCT02598427Phase 1Terminated
- Start
- May 2017
- Primary completion
- Feb 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pertuzumab in breast cancer and brain metastasis (BM). Primary endpoints: Adverse Events at 36 weeks and Maximum Tolerated Dose at 36 weeks. Started May 2017; status: terminated.
02
Drugs
pertuzumab
03
Conditions
breast cancerbrain metastasis (BM)
Beyond the preview
Go deeper on NCT02598427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02598427.